Chesapeake Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Chesapeake Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-25,031	Closed	-$474K	–	68
2017 Q4	$474K	Sell	25,031 -960	-4%	-$14.4K	0.46%	48
2017 Q3	$457K	Sell	25,991 -545	-2%	-$12.3K	0.41%	48
2017 Q2	$882K	Sell	26,536 -310	-1%	-$9.6K	0.84%	35
2017 Q1	$861K	Buy	+26,846	New	+$916K	0.71%	43
2013 Q3	–	Sell	-89,668	Closed	-$3.52M	–	79
2013 Q2	$3.52M	Buy	+89,668	New	+$3.49M	2.54%	10

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Chesapeake Asset Management's TEVA Position: Q1 2018 in Review

Chesapeake Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 25,031 shares — an estimated $474K sold.

Chesapeake Asset Management first reported a position in TEVA in Q2 2013 and held it in 5 quarters. The position peaked at $3.52M in Q2 2013. 507 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

Chesapeake Asset Management reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Chesapeake Asset Management sold 25,031 Teva Pharmaceuticals shares in Q1 2018, an estimated $474K.
Chesapeake Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 5 quarters.
Chesapeake Asset Management's Teva Pharmaceuticals position peaked at $3.52M in Q2 2013.
507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Chesapeake Asset Management's 13F filing for Q1 2018, filed 4 May 2018.